Roy Freeman joins AlgoTherapeutix’s Scientific Advisory Board.

AlgoTherapeutix announced today the appointment of Prof Roy Freeman to its Scientific Advisory Board.

Roy Freeman, MD.

Roy Freeman is Professor of Neurology at the Harvard Medical School and director of the Center for Autonomic and Peripheral Nerve Disorders in the Department of Neurology at Beth Israel Deaconess Medical Center in Boston, Massachusetts. 

His research and clinical interests are the physiology and pathophysiology of the small nerve fibers and the autonomic nervous system. His research encompasses the neurological complications of diabetes; neuropathic pain; the autonomic complications of Parkinson’s disease and multiple system atrophy; biomarkers in neurodegenerative diseases; and the diagnosis and treatment of autonomic and peripheral nervous system disorders. 

He has a special interest in clinical trial design in neuropathic pain in diabetic peripheral neuropathy and other peripheral nerve disorders. He has been principal investigator on many neuropathic pain clinical trials.  He is author of more than 200 original reports, chapters and reviews.

He is the principal investigator on National Institutes of Health-funded studies on the neurological complications of diabetes and biomarker development in alpha-synucleinopathies. 

Dr. Freeman is former chairman of the World Federation of Neurology research group on the autonomic nervous system, former president of the American Autonomic Society and former chairman of the Autonomic Section of the American Academy of Neurology.  He serves on the Executive Committee and the Steering Committee of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION), a public-private partnership with the United States FDA.  

He is Editor-in-Chief of Autonomic Neuroscience: Basic and Clinical and on the editorial boards of The Clinical Journal of Pain, Pain: Clinical Updates and Clinical Autonomic Research.

AlgoTherapeutix’ Scientific Advisory Board is chaired by Céline Greco (MD Phd), Hosp. Practitioner, Pain and Palliative Care Unit at the Hôpital Necker Enfants Malades in Paris. Céline heads up the Reference Center for Mastocytosis and Genetic Diseases with Cutaneous Expression. She is a laureate of the INSERM-Bettencourt school, and a Member of the Board  of the Council for Children Protection.

Roy Freeman joins the following members of the Scientific Advisory Board :

Philippe Arnaud, PharmD, is a Hospital Practitioner and Dpt Head at Bichat – Claude Bernard Hosp. He is a Professor at Paris Descartes Pharmacy & Biological Sciences University, and Erasmus teacher in Italy, Portugal and Canada. Philippe is a expert for the French National Medicines Agency (ANSM). 

Jean-François Bergmann is Professor of Therapeutics at Paris VII University. He headed up the Internal Medicine and Infectious Diseases Dpt at Hôpital Lariboisière, Paris. He is the President of the Medicines Committee of the Assistance Publique – Hôpitaux de Paris (AP-HP). He served as expert with the Drug Approval Committee and the Transparency Committee of the French National Medicines Agency (ANSM), and expert with the European Medicines Agency (EMA). 

Alain Eschalier is a pharmacist, a Medical Doctor and a Pharmacologist. He is Professor of Medical Pharmacology and former President of the Université d’Auvergne. Alain created and led several research units within INSERM and chairs the Analgesia Institute. 

Axel Le Cesne is Associate Professor of Medicine. Head of Medical Oncology Hospital Unit at Gustave Roussy, France. He headed the Bone/Soft Tissue Sarcoma Unit from 1995 to 2016. Axel is a member of ASCO, ESMO, EORTC Soft Tissue and Bone Sarcoma Group (STBSG). He served as Co-chair & Secretary of the French Sarcoma Group 2001-2005 and has been a member of the Board of Directors of the Connective Tissue Oncology Society since 2010. Axel is a member of French Academy of Medicine. 

Ronald Levy is Professor of Médecine, Stanford University Dpt of Oncology. He was awarded the Faisal International Prize, the Damashek Prize, the American Cancer Society’s Medal of Honor, the Leukemia and Lymphoma Society’s de Villiers Intl Achievement Award, the C. Chester Stock Award Memorial Sloan-Kettering Cancer Center, and the Karnofsky Award from the American Society of Clinical Oncology.

AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.

AlgoTherapeutix SAS

49 rue des Nouvelles – 92150 Suresnes

Contact- contact@algotx.com

Communication : Geneviève Cliquet Consultant – T: +33(0) 607 500 567

contact@cliquet-consultant.com